Skip to main content
SpringerLink
Log in

Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo

  • Original Articles
  • 5-Fluorouracil, Cisplatin, Reduced Folate, Antitumor Activity, Biochemical Modulation
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

The biochemical mechanism of the synergy of 5-fluorouracil (FUra) and cisplatin (CDDP) was studied using transplantable tumors in rodents in vivo. The reduced folate, 5,10-methylenetetrahydrofolate (CH2FH4) and its precursor tetrahydrofolate (FH4) are essential cofactors for the formation of a tight ternary complex of thymidylate synthase (TS) and 5-fluoro-2′-deoxyuridine-5′-monophosphate (FdUMP) derived from FUra. Intraperitoneal administration of CDDP (5 mg/kg) inhibited the incorporation of exogenousL-methionine into ascitic tumor cells and increased the levels of CH2FH4 and FH4 in ascitic Yoshida sarcoma and P-388 cells transplanted into rats and mice to levels about 2–3 times those measured in cells from animals that were not treated with CDDP. Preincubation with 10−6 M FUra in Hanks' medium inhibited [6-3H]-2′-deoxyuridine incorporation into DNA of tumor cells from CDDP-treated rats 3 times more than that into cells from untreated rats, indicating that the inhibition of TS by FdUMP derived from FUra was enhanced in the presence of CH2FH4. Intraperitoneal administration of CDDP on day 1 and continuous infusion of FUra from day 1 to day 6 had synergistic effects in inhibiting tumor growth in Yoshida sarcoma-bearing rats. Oral administration of UFT, a combined form of 1M tegafur and 4M uracil, for 7 consecutive days beginning at 24 h after tumor implantation and a single i.p. injection of CDDP on day 1 had a significantly greater effect than did either agent alone. These results suggest that CDDP significantly enhances FUra cytotoxicity by inhibiting intracellularL-methionine metabolism and consequently increasing the reduced folate pool in mammalian tumor models in vivo.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Butour JL, Macquet JP (1977) Differentiation of DNA-platinum complexes by fluorescence. The use of an intercalating dye as a probe. Eur J Biochem 78:455

    Google Scholar 

  2. Cantrell JE, Hart RD, Tayler RF, Harvey JH Jr (1987) Pilot trial of prolonged continuous-infusion 5-fluorouracil and weekly cisplatin in advanced colorectal cancer. Cancer Treat Rep 71:615

    Google Scholar 

  3. Carlson RW, Sikic BI (1983) Continuous infusion or bolus injection in cancer chemotherapy. Anal Int Med 99:823

    Google Scholar 

  4. Carrico CK, Glazer RI (1979) Effect of 5-fluorouracil on the synthesis and translation of polyadenylic acid-containing RNA from regenerating rat liver. Cancer Res 39:3694

    Google Scholar 

  5. Cohn J, Tester W, Desai A, Levik S, Andreas J (1988) Continuous infusion 5-fluorouracil and weekly low dose cisplatin in metastatic gastrointestinal malignancies. Proc Am Soc Clin Oncol 7:115

    Google Scholar 

  6. Duschinsky R, Pleven E, Heidelberger C (1957) The synthesis of 5-fluoropyrimidines. J Am Chem Soc 79:4559

    Google Scholar 

  7. Fujii S, Ikenaka K, Fukushima M, Shirasaka T (1978) Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil. Jpn J Cancer Res 69:763

    Google Scholar 

  8. Fujii S, Shimamoto Y, Ohshimo H, Imaoka T, Motoyama M, Fukushima M, Shirasaka T (1989) Effects of the plasma concentration of 5-fluorouracil and the duration of continuous venous infusion of 5-fluorouracil with an inhibitor of 5-fluorouracil degradation on Yoshida sarcoma in rats. Jpn J Cancer Res 80:167

    Google Scholar 

  9. Gonzalez-Brown M, Vicante J, Martin G (1990) Phase II trial of carboplatin and tegaful (ftorafur) as induction therapy in squamous-cell carcinoma of the head and neck. Am J Clin Oncol 13:277

    Google Scholar 

  10. Gonzalez-Brown M, Vicente J, Tomas M (1990) Phase II trial of cisplatin and tegaful (ftorafur) as initial therapy in squamous-cell carcinoma of the head and neck. Am J Clin Oncol 13:312

    Google Scholar 

  11. Greenberg B, Armann F, Garewall H, Koopmann C, Coulthard S, Berzes H, Alberts D, Shimm D (1987) Neoadjuvant therapy for advanced head and neck cancer with allopurinol-modulated high dose 5-fluorouracil and cisplatin. Cancer 59:1860

    Google Scholar 

  12. Hartman KY, Heidelberger C (1961) Studies on fluorinated pyrimidines: XII. Inhibition of thymidylate synthase. J Biol Chem 236:3006

    Google Scholar 

  13. Heim W, Brereton H, Shebaugh D (1986) Infusional high dose cis-platinum and 5-fluorouracil in advanced non-small cell lung cancer: a Mid-Atlantic Oncology Program pilot study. Proc Am Soc Clin Oncol 5:174

    Google Scholar 

  14. Kimura K, Suga S, Shimaji T, Kitamura M, Kubo K, Suzuoki Y, Isobe K (1980) Clinical basis of chemotherapy for gastric cancer with uracil and 1-(2-tetrahydrofuryl)-5-fluorouracil. Jpn Soc Gastroenterol 15:324

    Google Scholar 

  15. Kish J, Tapazoglou E (1985) Activity of 96 hour to 120 hour 5-fluorouracil infusion in advanced and recurrent head and neck cancer. Proc Am Soc Clin Oncol 4:130

    Google Scholar 

  16. Kish JA, Ensley JF, Jacobs JR, Binns P, Al-Sarraf M (1988) Evaluation of high-dose cisplatin and 5-FU infusion as initial therapy in advanced head and neck cancer. Am J Clin Oncol 11:553

    Google Scholar 

  17. Krebs HA, Hems R, Tyler B (1976) The regulation of folate and methionine metabolism. Biochem J 158:341

    Google Scholar 

  18. Langenback RJ, Danenberg PV, Heidelberger C (1972) Thymidylate synthase: mechanism of inhibition by 5-fluoro-2′-deoxyuridylate. Biochem Biophys Res Commun 48:1565

    Google Scholar 

  19. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JB (1989) A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program study. J Clin Oncol 7:425

    Google Scholar 

  20. Lorusso P, Pazdur R, Redman BG, Kinzie J, Vaitkevicius V (1989) Low-dose continuous infusion 5-fluorouracil and cisplatin: phase II evaluation in advanced colorectal carcinoma. Am J Clin Oncol 12:486

    Google Scholar 

  21. Maehara Y, Watanabe A, Kakeji Y, Baba H, Kohnoe S, Sugimachi K (1990) Postgastrectomy prescription of mitomycin C and UFT for patients with stage IV gastric carcinoma. Am J Surg 160:242

    Google Scholar 

  22. Naya KR, Nartin D, Stolfi R, Furth J, Spiegelman S (1978) Pyrimidine nucleosides enhance the anticancer activity of FU and augment its incorporation into nuclear RNA. Proc Am Assoc Cancer Res 19:63

    Google Scholar 

  23. Pratesi G, Gianni L, Manzotti C, Zunino F (1988) Sequence dependence of the antitumor and toxic effects of 5-fluorouracil andcis-diamminedichloroplatinum combination on primary colon tumors in mice. Cancer Chemother Pharmacol 21:237

    Google Scholar 

  24. Pratesi G, Manzotti C, Tortoreto M, Prosperi E, Zunino F (1989) Effects of 5-fluorouracil and cis-DDP combination on human colorectal tumor xenografts. Tumori 75:60

    Google Scholar 

  25. Priest DG, Veronee CD, Mangum M, Bednarek JM, Doig MT (1982) Comparison of folylpolyglutamate hydrolase of mouse liver, kidney, muscle and brain. Mol Cell Biochem 43:81

    Google Scholar 

  26. Riviere A, Abouz D, Ayela P, Berthand P, Frenay M, Lagrange JL, Pujol JL, Robillard J, Lechevalier T (1989) Resultants d'une etude de phase II d'une association de cis-platinum et de 5-FU les cancers bronchiques epidermoides on indifferencies a grades cellules. Bull Cancer (Paris) 76:1095

    Google Scholar 

  27. Rooney M, Kish J, Jacobs J, Kinzie J, Weaver A, Crissman J, Al-Sarraf M (1985) Improved complete response rates and survival in advanced head and neck cancer after three-course induction therapy with 120 hours 5-FU infusion and cisplatin. Cancer 55:1123

    Google Scholar 

  28. Santi DV, McHenry CS (1972) 5-Fluoro-2′-deoxyuridylate: covalent complex with thymidylate synthase. Proc Natl Acad Sci USA 69:1855

    Google Scholar 

  29. Scanlon KJ, Safirstein RL, Thies H, Gross RB, Waxman S, Guttenplan JB (1983) Inhibition of amino acid transport bycis-diamminedichloroplatinum(II) derivatives in L1210 murine leukemia cells. Cancer Res 43:4211

    Google Scholar 

  30. Scanlon KJ, Newman EM, Lu Y, Priest DG (1986) Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 83:8923

    Google Scholar 

  31. Schneider WC (1946) Phosphorous compounds in animal tissues: III. Comparison of methods for the estimation of nucleic acids. J Biol Chem 164:747

    Google Scholar 

  32. Seifert P, Baker LH, Reed ML, Vaitkevicius VK (1975) Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer 36:123

    Google Scholar 

  33. Spears CP, Shahinian AH, Moran RG, Heidelberger C, Corbett TH (1982) In vivo kinetics of thymidylate synthase inhibition in 5-fluorouracil-sensitive and-resistant murine colon adenocarcinomas. Cancer Res 43:450

    Google Scholar 

  34. Spears CP, Gustavsson BG, Mitchell MS, Spicer D, Berone M, Bernstein L, Danenberg DV (1984) Thymidylate synthase inhibition in malignant tumors and normal liver of patients given intravenous 5-fluorouracil. Cancer Res 44:4144

    Google Scholar 

  35. Spears CP, Gustavsson BG, Berne M, Trosing R, Bernstein L, Hayes AA (1988) Mechanism of innate resistance to thymidylate synthase inhibition after 5-fluorouracil. Cancer Res 48:5894

    Google Scholar 

  36. Sullivan RD, Young CW, Miller E (1960) The clinical effects of continuous administration of fluorinated pyrimidines (5-fluorouracil and 5-fluoro-2′-deoxyuridine). Cancer Chemother Rep 8:77

    Google Scholar 

  37. Tatsumi K, Kukushima M, Shirasaka T, Fujii S (1987) Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res 78:748

    Google Scholar 

  38. Thomas GD, Paterson ICM (1988) Response rates and survival in patients with head and neck cancer treated with a combination of cisplatin and 5-fluorouracil prior to radiotherapy. Clin Radiol 39:551

    Google Scholar 

  39. Weaver A, Fleming S, Ensley J, Kinzie J, Crissman J, Al-Sarraf M (1984) Superior clinical response and survival rates with initial bolus cisplatin and 120 hour infusion of 5-fluorouracil before definitive therapy for locally advanced head and neck cancer. Am J Surg 148:525

    Google Scholar 

  40. Weiden PL, Einstein AB, Rudolph RH (1985) Cisplatin bolus and 5-FU infusion chemotherapy for non-small cell lung cancer. Cancer Treat Rep 69:1253

    Google Scholar 

  41. Wilkinson DS, Tlsty TD, Hanas RJ (1975) The inhibition of ribosomal RNA synthesis and maturation in Novikoff hepatoma cells by 5-fluorouridine. Cancer Res 35:3014

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute for Pathogenic Biochemistry in Medicine, Taiho Pharmaceutical Co., Ltd., Misugidai, 357, Hanno-city, Saitama, Japan

    Tetsuhiko Shirasaka, Yuji Shimamoto, Hideyuki Ohshimo, Hiroko Saito & Masakazu Fukushima

Authors
  1. Tetsuhiko Shirasaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yuji Shimamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hideyuki Ohshimo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hiroko Saito
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Masakazu Fukushima
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shirasaka, T., Shimamoto, Y., Ohshimo, H. et al. Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo. Cancer Chemother. Pharmacol. 32, 167–172 (1993). https://doi.org/10.1007/BF00685830

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00685830

Keywords

Search

Navigation